Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Growth Graph by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Cancer Immunotherapy Drug Discovery Outsourcing Market Size Analysis

Global Cancer Immunotherapy Drug Discovery Outsourcing Market Introduction
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Head and Neck
  1. By Value
8. Ovarian
  1. By Value
9. Pancreatic
  1. By Value
10. Othe Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Cancer Vaccines and Oncolytic Viral Therapy
  1. By Value
5. Other Drug Types
  1. By Value

North America Market Analysis

Introduction
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Head and Neck
  1. By Value
8. Ovarian
  1. By Value
9. Pancreatic
  1. By Value
10. Othe Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Cancer Vaccines and Oncolytic Viral Therapy
  1. By Value
5. Other Drug Types
  1. By Value
U.S.
1. By Service Type
  1. Introduction
    1. Service Type By Value
  2. Target Identification and Validation
    1. By Value
  3. Lead Screening and Characterization
    1. By Value
  4. Cell-based Assays
    1. By Value
2. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Lung
    1. By Value
  3. Breast
    1. By Value
  4. Colorectal
    1. By Value
  5. Melanoma
    1. By Value
  6. Prostate
    1. By Value
  7. Head and Neck
    1. By Value
  8. Ovarian
    1. By Value
  9. Pancreatic
    1. By Value
  10. Othe Types
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Immunomodulators
    1. By Value
  4. Cancer Vaccines and Oncolytic Viral Therapy
    1. By Value
  5. Other Drug Types
    1. By Value
Canada

Europe Market Analysis

Introduction
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Head and Neck
  1. By Value
8. Ovarian
  1. By Value
9. Pancreatic
  1. By Value
10. Othe Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Cancer Vaccines and Oncolytic Viral Therapy
  1. By Value
5. Other Drug Types
  1. By Value
U.K.
1. By Service Type
  1. Introduction
    1. Service Type By Value
  2. Target Identification and Validation
    1. By Value
  3. Lead Screening and Characterization
    1. By Value
  4. Cell-based Assays
    1. By Value
2. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Lung
    1. By Value
  3. Breast
    1. By Value
  4. Colorectal
    1. By Value
  5. Melanoma
    1. By Value
  6. Prostate
    1. By Value
  7. Head and Neck
    1. By Value
  8. Ovarian
    1. By Value
  9. Pancreatic
    1. By Value
  10. Othe Types
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Immunomodulators
    1. By Value
  4. Cancer Vaccines and Oncolytic Viral Therapy
    1. By Value
  5. Other Drug Types
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Head and Neck
  1. By Value
8. Ovarian
  1. By Value
9. Pancreatic
  1. By Value
10. Othe Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Cancer Vaccines and Oncolytic Viral Therapy
  1. By Value
5. Other Drug Types
  1. By Value
China
1. By Service Type
  1. Introduction
    1. Service Type By Value
  2. Target Identification and Validation
    1. By Value
  3. Lead Screening and Characterization
    1. By Value
  4. Cell-based Assays
    1. By Value
2. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Lung
    1. By Value
  3. Breast
    1. By Value
  4. Colorectal
    1. By Value
  5. Melanoma
    1. By Value
  6. Prostate
    1. By Value
  7. Head and Neck
    1. By Value
  8. Ovarian
    1. By Value
  9. Pancreatic
    1. By Value
  10. Othe Types
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Immunomodulators
    1. By Value
  4. Cancer Vaccines and Oncolytic Viral Therapy
    1. By Value
  5. Other Drug Types
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Head and Neck
  1. By Value
8. Ovarian
  1. By Value
9. Pancreatic
  1. By Value
10. Othe Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Cancer Vaccines and Oncolytic Viral Therapy
  1. By Value
5. Other Drug Types
  1. By Value
UAE
1. By Service Type
  1. Introduction
    1. Service Type By Value
  2. Target Identification and Validation
    1. By Value
  3. Lead Screening and Characterization
    1. By Value
  4. Cell-based Assays
    1. By Value
2. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Lung
    1. By Value
  3. Breast
    1. By Value
  4. Colorectal
    1. By Value
  5. Melanoma
    1. By Value
  6. Prostate
    1. By Value
  7. Head and Neck
    1. By Value
  8. Ovarian
    1. By Value
  9. Pancreatic
    1. By Value
  10. Othe Types
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Immunomodulators
    1. By Value
  4. Cancer Vaccines and Oncolytic Viral Therapy
    1. By Value
  5. Other Drug Types
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Service Type
1. Introduction
  1. Service Type By Value
2. Target Identification and Validation
  1. By Value
3. Lead Screening and Characterization
  1. By Value
4. Cell-based Assays
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Lung
  1. By Value
3. Breast
  1. By Value
4. Colorectal
  1. By Value
5. Melanoma
  1. By Value
6. Prostate
  1. By Value
7. Head and Neck
  1. By Value
8. Ovarian
  1. By Value
9. Pancreatic
  1. By Value
10. Othe Types
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Monoclonal Antibodies
  1. By Value
3. Immunomodulators
  1. By Value
4. Cancer Vaccines and Oncolytic Viral Therapy
  1. By Value
5. Other Drug Types
  1. By Value
Brazil
1. By Service Type
  1. Introduction
    1. Service Type By Value
  2. Target Identification and Validation
    1. By Value
  3. Lead Screening and Characterization
    1. By Value
  4. Cell-based Assays
    1. By Value
2. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Lung
    1. By Value
  3. Breast
    1. By Value
  4. Colorectal
    1. By Value
  5. Melanoma
    1. By Value
  6. Prostate
    1. By Value
  7. Head and Neck
    1. By Value
  8. Ovarian
    1. By Value
  9. Pancreatic
    1. By Value
  10. Othe Types
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Monoclonal Antibodies
    1. By Value
  3. Immunomodulators
    1. By Value
  4. Cancer Vaccines and Oncolytic Viral Therapy
    1. By Value
  5. Other Drug Types
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Cancer Immunotherapy Drug Discovery Outsourcing Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Covance Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Crown Bioscience Inc.
Horizon Discovery Group plc
GenScript Biotech Corporation
BPS Bioscience Inc.
HD Biosciences Co. Ltd.
Promega Corporation
DiscoverX Corporation
Explicyte
ImmunXperts SA
Celentyx Ltd.
Aquila BioMedical
STC Biologics
Personalis Inc.
Molecular Imaging Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment